Verus Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
Verus Capital Partners's ABBV Position: Q3 2026 in Review
Verus Capital Partners increased its AbbVie (ABBV) stake by 0.45% in Q3 2026, buying an estimated $55.4K and bringing the position to 48,145 shares worth $12.6M. The position accounts for 0.66% of the portfolio, ranked #27.
Verus Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 21 quarters since. The position peaked at $15M in Q1 2022. 4,272 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Verus Capital Partners held 48,145 shares of AbbVie worth $12.6M as of Q3 2026.
- Verus Capital Partners bought 216 AbbVie shares in Q3 2026, an estimated $55.4K.
- AbbVie made up 0.66% of Verus Capital Partners's portfolio in Q3 2026, its #27 holding.
- Verus Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 21 quarters since.
- Verus Capital Partners's AbbVie position peaked at $15M in Q1 2022.
- 4,272 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Verus Capital Partners's 13F filing for Q3 2026, filed 3 Nov 2026.